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Purpose: The therapeutic regimen for cranial arteriovenous malformations often involves both
stereotactic radiosurgery and endovascular embolization. Embolization agents may contain tantalum
or other contrast agents to assist the neurointerventionalists, leading to concerns regarding the dosi-
metric effects of these agents. This study investigated dosimetric properties of n-butyl cyanoacrylate
(n-BCA) plus lipiodol with and without tantalum powder.
Methods: The embolization agents were provided cured from the manufacturer with and without
added tantalum. Attenuation measurements were made for the samples and compared to the attenu-
ation of a solid water substitute using a 6 MV photon beam. Effective linear attenuation coefficients
(ELAC) were derived from attenuation measurements made using a portal imager and derived sample
thickness maps projected in an identical geometry. Probable dosimetric errors for calculations in
which the embolized regions are overridden with the properties of water were calculated using the
ELAC values. Interface effects were investigated using a parallel plate ion chamber placed at set
distances below fixed samples. Finally, Hounsfield units (HU) were measured using a stereotactic
radiosurgery CT protocol, and more appropriate HU values were derived from the ELAC results and
the CT scanner’s HU calibration curve.
Results: The ELAC was 0.0516±0.0063 cm−1 and 0.0580±0.0091 cm−1 for n-BCA without and
with tantalum, respectively, compared to 0.0487±0.0009 cm−1 for the water substitute. Dose calcu-
lations with the embolized region set to be water equivalent in the treatment planning system would
result in errors of −0.29% and −0.93% per cm thickness of n-BCA without and with tantalum,
respectively. Interface effects compared to water were small in magnitude and limited in distance
for both embolization materials. CT values at 120 kVp were 2082 and 2358 HU for n-BCA without
and with tantalum, respectively; dosimetrically appropriate HU values were estimated to be 79 and
199 HU, respectively.
Conclusions: The dosimetric properties of the embolization agents are very close to those of water
for a 6 MV beam. Therefore, treating the entire intracranial space as uniform in composition will
result in less than 1% dosimetric error for n-BCA emboli smaller than 3.4 cm without added tantalum
and n-BCA emboli smaller than 1.1 cm with added tantalum. Furthermore, when effective emboli-
zation can be achieved by the neurointerventionalist using n-BCA without tantalum, the dosimetric
impact of overriding material properties will be lessened. However, due to the high attenuation of
embolization agents with and without added tantalum for diagnostic energies, artifacts may occur
that necessitate additional imaging to accurately identify the spatial extent of the region to be treated.
C 2015 American Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4915080]
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1. INTRODUCTION
Arteriovenous malformations (AVMs) are collections of
abnormal arteries and veins (and the resulting nidus) that do
not connect through the normal intervening capillary bed.
Cerebral AVMs are often discovered after an intracerebral
hemorrhage, the risk of which has been shown to be between
2% and 4% annually.1,2 The combined morbidity and mortality
per bleed event can approach 50%.3
The therapeutic regimen for cranial AVMs often involves
both stereotactic radiosurgery and endovascular embolization,
with the goal of eventual complete obliteration of the AVM
nidus due to embolization and scarring. Two common com-
mercially available embolization agents are Onyx (ethylene-
vinyl alcohol copolymer) and n-butyl cyanoacrylate (n-BCA).
The Onyx material comes with added tantalum (Z = 73)
powder to aid neurointerventional radiologists in visualization
on fluoroscopy during embolization, and the n-BCA agents
can be cured with iodinated oil (lipiodol) and can also have
tantalum powder added.
Published reports have suggested lower obliteration rates
after neoadjuvant embolization4–7 and raised concerns as to the
dosimetric effects of embolization agents with added high-Z
materials.8,9 Partly in answer to these reports, a study was
published by Roberts et al.10 that quantified the dosimetric
effects of Onyx on therapeutic-energy radiation. Onyx embo-
lization agents of two different viscosity levels were found to
have clinically negligible dosimetric consequences for smaller
effective thickness values, with down-stream transmission
reduced by up to 10% for ≥2 cm thicknesses of Onyx. The
present report aims to apply similar methodology to quantify
the dosimetric consequences of a commercially available n-
BCA embolization agent cured with lipiodol, both with and
without the addition of tantalum powder.
2. METHODS AND MATERIALS
As n-BCA is a type of glue, it needs to be cured before
it will set and solidify. In the human body, blood is the
main curing agent, though oil may be mixed into the n-BCA
for curing purposes. For this study, the two samples of n-
BCA were provided from the manufacturer (Codman Trufill;
Codman & Shurtleff, Inc., Raynham, MA) cured with lipiodol,
a poppy seed oil containing iodine (Z = 53), one with and
one without added tantalum. These samples will be denoted
as n-BCA-Ta and n-BCA, respectively. The samples were
approximately 10 cm in diameter and 5 mm thick. A figure of
the n-BCA sample is shown in Fig. 1.
2.A. Imaging studies
The n-BCA and n-BCA-Ta samples were imaged using a
CT simulator (Philips Big Bore CT scanner; Philips Medical
Systems, Cleveland, OH) using modified versions of an SRS
imaging protocol (1 mm contiguous slices, 400 mAs, 90, 120,
or 140 kVp). The samples were sandwiched between two
5 cm slabs of Solid Water (Gammex, Middleton, WI). Average
Hounsfield unit (HU) values were acquired in a central 7 cm
F. 1. Photograph of the cured n-BCA sample provided by the manufac-
turer.
diameter circular ROI using 5 mm averaged coronal slices
through the center of the samples. Using the scanner’s HU-
to-electron density table, generated at time of CT scanner
commissioning, we calculated the apparent electron densities
for Solid Water, n-BCA, and n-BCA-Ta from the tabulated
HU values.
Additionally, the samples were imaged in a water bath
using a 3T MR system (Siemens Skyra) using both a stan-
dard T1-weighted pulse sequence and a time-of-flight pulse
sequence (typical for AVM patients) to evaluate image quality
with the embolization agents.
2.B. Effective linear attenuation measurements
A 6 MV photon beam was used from a Varian Clinac
EX (Varian Medical Systems, Palo Alto, CA) to measure at-
tenuation of the n-BCA samples and of Solid Water. Higher
energy measurements were not made, since SRS procedures
use the 6 MV photon beam in many clinics. In the previous
report by Roberts et al.,10 transmission measurements were
made using an ionization chamber and Solid Water. Linear
attenuation coefficients were calculated from the transmission
and measured thickness. However, the n-BCA samples
exhibited heterogeneous thickness readings across the sample
diameter (see Fig. 1). Linear attenuation coefficients derived
using similar methodology to Roberts et al. resulted in
unacceptably large error bars on attenuation coefficients due
to the large variability in sample thickness.
For this study, attenuation coefficients were calculated
using transmission maps made from the ratio of portal images
from the Linac’s MV imager panel. The 6 MV image of
the sample was divided by a 6 MV image of an open field
of identical dimensions. For imaging purposes, the n-BCA
samples were suspended using plastic wrap halfway between
the radiation source and the imager panel. The resulting ratio
between the image of the sample and the open field image
characterized the transmission across the sample disc.
The thickness of each sample was mapped by ray-tracing
the CT scans of the n-BCA samples after thresholding.
Thresholding was applied such that HU values above 1000
were classified as sample, and HU values below 1000 were
classified as nonsample. This particular threshold value was
derived from HU value line profiles through the samples and
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F. 2. Graphical description of the process used to calculate linear attenuation coefficient maps. Left side: transmission maps are generated by acquiring an MV
image of the sample (S) using a 6 MV Linac beam and normalizing to an open field. Right side: thickness maps are generated by ray tracing through the masked
3D CT dataset from a virtual source under identical geometry to the transmission map measurements. The two maps are combined to form the attenuation
coefficient (µ) map.
visual identification of where the sample started and stopped.
The segmentation process was insensitive to the exact value
of the threshold. The resulting segmented sample volume
was virtually projected in a cone-beam geometry onto an
image matrix identically sized to the actual acquired portal
images (same pixel pitch, same source-to-imager distance,
etc.). The thickness was derived by multiplying this projected
sum image by the oblique voxel thickness as a function of
off-axis position.
The two images (thickness map and transmission map)
were manually registered by point matching to visible land-
marks (such as cracks) in the samples using the freely avail-
able software ImageJ (version 1.48, http://imagej.nih.gov/ij/).
After registration, the linear attenuation coefficient µ was
calculated using the standard formula (see Fig. 2). The un-
certainty in µ was calculated using spatial statistics in manual
regions of interest.
2.C. Dosimetric deviations from homogeneous
calculations
Based on the effective linear attenuation coefficients de-
rived from the above analysis, the dosimetric consequence
can be calculated if one were to assume a homogeneous water-
equivalent composition inside the embolization material. Due
to the streak artifacts sometimes observed in the proximity of
these embolization agents, users may be tempted to override
the density inside the embolized volume with that of water
or to simply perform all dose calculations without density
correction. In reality, while the n-BCA samples have slightly
higher attenuation than water, their attenuation properties in a
6 MV beam are not accurately represented by their apparent
HU value from a diagnostic energy CT image. The presence
of high atomic number additives (iodine is present in both
samples, and tantalum is present in the n-BCA-Ta sample)
leads to increased photoelectric interaction, whereas MV
interactions are predominantly Compton-based.
The dosimetric deviations for assumed homogeneous
densities were calculated by taking the transmission ratio of an
identical thickness of embolization material with that of Solid
Water. If the attenuation of a certain thickness of embolization
agent is greater than that of water, the dose deviation will
be a negative value; the “true dose” will be less than that
reported by the homogeneous dose calculation. Uncertainties
on this dose deviation are calculated by propagating the error
found in the linear attenuation coefficient measurements. Note
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F. 3. Experimental setup for measuring interface effects. The parallel plate
chamber (“A11”) was placed below the sample S (n-BCA, n-BCA-Ta, or
Solid Water) and a variable thickness of Solid Water.
that this particular experiment only refers to dose deviations
due to overriding the density of the embolization agent itself,
not including any deviations that may arise when setting the
entire patient volume to water-equivalent material (e.g., not
accounting for bony anatomy).
2.D. Interface effects
Interface effects were investigated using a parallel plate ion
chamber (Exradin A11; Standard Imaging, Middleton, WI)
placed below the various samples and a variable thickness
of Solid Water. The experimental setup is shown in Fig. 3.
The sample “S” (n-BCA, n-BCA-Ta, or a 1 cm Solid Water
piece) was placed on top of a variable thickness of Solid
Water, and the whole setup was irradiated with a 5×5 cm
field size (enough to fully encompass the ionization chamber
but not excessively irradiate the stem). Measurements using
the n-BCA samples were compared to measurements using
the Solid Water piece as the sample S to calculate the relative
enhancement from the presence of the embolization agent.
Prior to this comparison, the measurements acquired with
the 1 cm Solid Water piece as the sample S were corrected
using TPR ratios to derive measurements that would have
been acquired with a Solid Water sample piece equal in
thickness to the n-BCA samples. The net uncertainty in the
interface effect calculation included all relevant measure-
ment uncertainty, as well as uncertainty from the n-BCA
sample thicknesses used in the TPR corrections mentioned
above.
F. 4. Images of the n-BCA sample. (a) Axial CT view with window set to
[−1000,1000] HU, (b) same as (a), except with window [−1000,2500] HU,
(c) sample sealed in a plastic bag, submerged in water, and imaged using a
T1-weighted MR protocol, and (d) sample imaged using a time-of-flight MR
protocol (typical for AVM patients). The slight apparent artifacts around the
sample in (d) are likely due to air trapped in plastic bag.
3. RESULTS
Imaging results from the n-BCA samples are shown in
Fig. 4. Streaks can be seen emanating from the samples in
the CT images, but the MR images appear largely artifact-free
except for some slight susceptibility artifact on the periphery
of the sample, where some air was trapped in the plastic bag
used to protect the sample from the surrounding water bath.
The extracted HU values, along with apparent relative electron
densities from our scanner’s HU-to-electron density curve, are
given in Table I.
Figure 5 shows the transmission map of the n-BCA sample,
along with the projected thickness map and the derived
linear attenuation coefficient map. Both the thickness map
and transmission map generation techniques were validated
to within 2% using Solid Water samples under identical
geometry conditions to the n-BCA samples. Figure 5(c) shows
some nonuniformity in regions of low thickness; we believe
that the sample is not rigidly stable in regions of very low
thickness and we therefore excluded those regions from our
linear attenuation coefficient extraction. The linear attenuation
coefficient results are shown in Table II.
T I. Extracted HU values and apparent relative electron densities from CT scans of n-BCA samples and Solid
Water.
90 kVp 120 kVp 140 kVp
Material HU ± SD ρe (relative) HU ± SD ρe (relative) HU ± SD ρe (relative)
Solid Water 28 ± 9 1.05 24 ± 9 1.05 34 ± 10 1.06
n-BCA 2285 ± 1012 2.44 2082 ± 880 2.31 2119 ± 797 2.34
n-BCA-Ta 2339 ± 950 2.47 2358 ± 913 2.49 2233 ± 812 2.41
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F. 5. Property maps of the n-BCA sample. (a) Transmission map (unitless), (b) projected thickness map in millimeters, and (c) derived linear attenuation
coefficient map (unitless).
T II. Linear attenuation coefficients of materials measured in this study.
Material Linear attenuation coefficient µ (cm−1)
Liquid watera 0.04942
Solid Water 0.0487 ± 0.0009
n-BCA 0.0516 ± 0.0063
n-BCA-Ta 0.0580 ± 0.0091
aThe liquid water attenuation coefficient is given only for reference and was
taken from NIST Physical Reference Data (http://physics.nist.gov/PhysRefData/
XrayMassCoef/ComTab/water.html).
F. 6. Probable error in dose calculation resulting from assignment of
water-equivalent density to the embolization agents. Negative values indicate
that the true dose with the embolization agent present would be lower than
that calculated with water-equivalent density. Dashed lines are one standard
deviation.
F. 7. Relative enhancement over water from the n-BCA embolization
agent. For experimental setup, see Fig. 3. The dashed lines are single standard
deviation error bars.
We also calculated the “appropriate HU values” for the
embolization agents (that is, the HU values that would appro-
priately represent the 6 MV attenuation characteristics of the
samples). As Compton interactions are proportional to elect-
ron density, we used the ratios of attenuation coefficients in
Table II and the known density of Solid Water to calculate that
the appropriate (relative) electron density is 1.11 and 1.25 for
n-BCA and n-BCA-Ta, respectively. Using the inverse of the
HU-to-electron density curve for our CT scanner, we found
the appropriate HU values to be 79±120 HU for the n-BCA
sample and 199±172 HU for the n-BCA-Ta sample.
Based on the linear attenuation properties of the n-BCA
embolization agents, the dosimetric discrepancy introduced
by overriding the embolization material with water-equivalent
density is shown in Fig. 6. Since the point estimate of µ for
the embolization agents is larger than that of Solid Water, the
true dose when the embolization agents are present will be
lower than the dose calculated under the assumption that the
embolization agents are water-equivalent. Such dose calcula-
tions would result in errors of −0.29% and −0.93% per cm
thickness of embolization agent without and with tantalum,
respectively.
The interface effects for the n-BCA sample are quantified in
Fig. 7. The relative enhancement over water in Fig. 7 was taken
as the difference of the measurement ratio from unity. Within
the first few millimeters, the interface enhancement quickly
approaches zero (within the measurement uncertainty). The
plot for the n-BCA-Ta sample exhibited similar behavior,
but the deviation from null enhancement in the first few
millimeters is less pronounced.
4. DISCUSSION AND CONCLUSIONS
This study investigated the dosimetric effects of two
embolization agents used in arteriovenous malformations.
Both embolization agents are made from n-BCA cured with
an iodinated oil, one with and one without added tantalum
powder. While the dosimetric properties of other embolization
agents (i.e., Onyx) have been investigated previously,10 this
work represents the first dosimetric study of n-BCA emboli-
zation materials. The materials in this study showed markedly
Medical Physics, Vol. 42, No. 4, April 2015
1744 Labby et al.: Dosimetric measurements of an n-BCA embolization material 1744
less attenuation at 6 MV beam energies than Onyx materials
(e.g., compare Table II in this study to Fig. 7 in the report by
Roberts et al.) with interface effects of similar magnitude.
Simple attenuation measurement techniques, such as bulk
attenuation measurements at a single or small set of measure-
ment points below a sample, were not used in this study due to
the texture inherent in the cured n-BCA samples (see Fig. 1).
Instead, a thickness mapping technique was developed for
this work, and the resulting attenuation map of the sample
appeared to be robust outside of very thin sample regions.
Very thin sections of the samples were, for lack of a better
word, crumbly.
This study provides effective attenuation coefficients for
n-BCA embolization agents for a 6 MV beam, as well as quan-
tifies the interface effects in the immediate proximity of the
embolization agents. For first-order effects due to attenuation
differences, the abscissa of Fig. 6 was chosen to represent the
range of typical AVM masses (1–3 cm), where the probable
error peaks at−0.87% and−2.75% for n-BCA samples without
and with tantalum, respectively. As shown in Fig. 7, the dose on
the distal (downstream) interface of the embolization material
is slightly lower than that for an equivalent amount of water
replacing the embolization agent. The same effect is observed
for both n-BCA and n-BCA-Ta, though the effect is more pro-
nounced with n-BCA. The observed deficit could be explained
by increased attenuation and the rebuildup of electron fluence
past the interface with the textured sample (see Fig. 1), though
no matter the cause, the magnitude of the interface effect is
below the threshold of clinical relevance.
This work provides derived relative electron densities for
the embolization agents, as well as HU values that could be
used to override the densities assigned by the treatment plan-
ning system based on the CT scan alone. The HU values
provided above are only strictly relevant for the HU-to-
electron density curve associated with the CT scanner used
in this study. Any readers interested in overriding regions
of n-BCA embolization agents with dosimetrically appropri-
ate image values are encouraged to either use the electron
densities calculated above directly (if supported by the
treatment planning system) or to find appropriate HU values
based on the user’s own CT scanner calibration curve.
With regards to the selection of n-BCA agents with and
without tantalum, anecdotal feedback from some radiologists
suggests that the addition of tantalum powder is not necessary
for visualization during embolization on fluoroscopy. This
finding suggests that n-BCA without tantalum could be used
on a routine basis, thereby mitigating the increased dosime-
tric discrepancy observed with the addition of tantalum.
Subjectively, the n-BCA without tantalum also exhibited
fewer streak artifacts in the acquired CT scan. However, both
n-BCA agents did exhibit at least some streaking in the CT
images, and other reports have indicated that target delinea-
tion on CT can be made difficult by embolization agents with
high atomic number components.11 Image fusion with other
imaging modalities (e.g., magnetic resonance imaging or
angiography, CT angiography, etc.) is therefore recommended
for appropriate delineation of target boundaries.
While the dosimetric effects of the n-BCA embolization
agents in this study are small for a 6 MV beam, the discre-
pancies from standard water dosimetry are slightly larger
for n-BCA with added tantalum. Data are provided in this
report to understand the dosimetric consequences of the
embolization agents, as well as to override the values of CT
images in embolized regions with dosimetrically appropriate
values. Finally, imaging studies showed that embolized re-
gions may require imaging beyond CT (such as MRI) to ap-
propriately identify targets obfuscated by streak artifacts.
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